Medically reviewed on Nov 15, 2018
(sye kloe SER een)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Generic: 250 mg
- Antibiotic, Miscellaneous
- Antitubercular Agent
Inhibits bacterial cell wall synthesis by competing with amino acid (D-alanine) for incorporation into the bacterial cell wall; bacteriostatic or bactericidal
~70% to 90% from GI tract (WHO 2008)
Widely to most body fluids and tissues including CSF, bile, sputum, lymph tissue, lungs, and ascitic, pleural, and synovial fluids (WHO 2008)
Urine (~65% as unchanged drug) within 72 hours; Feces (small amounts); remainder metabolized
Time to Peak
Serum: 4 to 8 hours
Normal renal function: 12 hours
Not plasma protein bound
Use: Labeled Indications
Tuberculosis: Treatment of active pulmonary or extrapulmonary tuberculosis, in combination with other agents, when treatment with primary tuberculosis therapy has proved inadequate
Urinary tract infections: May be effective in treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram-negative bacteria, especially Enterobacter spp. and Escherichia coli. Note: Should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.
Hypersensitivity to cycloserine or any component of the formulation; epilepsy; depression, severe anxiety, or psychosis; severe renal insufficiency; excessive concurrent use of alcohol
Tuberculosis, active (alternative agent): Oral:
10 to 15 mg/kg/day (maximum: 1,000 mg/day), usually 250 to 500 mg once or twice daily (ATS/CDC/IDSA [Nahid 2016]). Note: Experienced clinicians indicate most patients are unable to tolerate the 500 mg twice daily dose and recommend the following 2-week dose titration: 250 mg once daily for 3 to 4 days, 250 mg every 12 hours for 3 to 4 days, then 250 mg in the morning and 500 mg in the evening (Curry International Tuberculosis Center 2016; Drew 2017). Peak (2 hours post-dose) serum concentrations targeted at 20 to 35 mcg/mL are often useful in determining the optimal dose (ATS 2003; Curry International Tuberculosis Center 2016).
Note: Some neurotoxic effects may be treated or prevented by concomitant administration of 200 to 300 mg of pyridoxine daily or 50 mg of pyridoxine per 250 mg of cycloserine (Curry International Tuberculosis Center 2016; WHO 2008).
Manufacturer's labeling: Dosing in the prescribing information may not reflect current clinical practice. Initial: 250 mg every 12 hours for 14 days, then administer 500 to 1,000 mg/day in 2 divided doses (maximum: 1,000 mg/day)
Urinary tract infections: Oral: There is no dosage provided in the prescribing information. Note: Should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug.
Refer to adult dosing.
Active tuberculosis infection (excluding meningitis); treatment (second-line therapy): Limited data available: Note: Recommendations often change due to epidemiology (resistance) and emerging information; consult CDC and WHO for current recommendations for detailed information. Always use as part of a multidrug regimen (ATS/CDC/IDSA [Nahid 2016]). Concomitant pyridoxine is recommended to prevent cycloserine-induced neuropathy (WHO 2009).
Infants, Children, and Adolescents <15 years of age weighing ≤40 kg: Oral: 15 to 20 mg/kg/day divided every 12 to 24 hours (if tolerability issues, may divide into 2 doses); maximum daily dose: 1,000 mg/day (ATS/CDC/IDSA 2016; HHS [pediatric 2013]; Seddon 2012). Note: Some patients may be unable to tolerate recommended doses; experts suggest beginning with a low once daily dose and gradually increasing as tolerated; serum concentrations targeted at 25 to 30 mcg/mL have been suggested to minimize toxicity (ATS/CDC/IDSA [Nahid 2016]; HHS [pediatric 2013]).
Children and Adolescents <15 years of age weighing >40 kg or Adolescents ≥15 years of age: Oral: 10 to 15 mg/kg/day divided every 12 to 24 hours; usual dose 250 to 500 mg; maximum daily dose: 1,000 mg/day. Note: Patients are often unable to tolerate the maximum dose divided twice daily (eg, in adults, 500 mg twice daily); therefore, experts suggest beginning with a low once daily dose and gradually increasing as tolerated; may consider therapeutic drug monitoring; serum concentrations targeted at 25 to 30 mcg/mL have been suggested to minimize toxicity (ATS/CDC/IDSA [Nahid 2016]; HHS [pediatric 2013]).
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer’s labeling; use is contraindicated in severe impairment. However, the following adjustments have been used by some clinicians:
Nahid 2016: CrCl <30 mL/minute or hemodialysis: 250 mg once daily, or 500 mg 3 times per week. Note: The efficacy of 250 mg daily doses has not been established, and careful monitoring is necessary for evidence of neurotoxicity. Monitor serum concentrations to minimize toxicity.
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer’s labeling.
Administer orally in divided doses with or without food.
May be taken with food; may increase vitamin B12 and folic acid dietary requirements.
Store at 20°C to 25°C (68°F to 77°F).
Alcohol (Ethyl): May enhance the neurotoxic effect of CycloSERINE. Specifically, the risk for seizures may be increased. Avoid combination
BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Avoid combination
BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Monitor therapy
Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Avoid combination
Ethionamide: May enhance the adverse/toxic effect of CycloSERINE. Monitor therapy
Isoniazid: May enhance the adverse/toxic effect of CycloSERINE. Specifically, CNS toxicity may be enhanced. Monitor therapy
Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Monitor therapy
Prothionamide: May enhance the adverse/toxic effect of CycloSERINE. Monitor therapy
Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Consider therapy modification
Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents. Consider therapy modification
Frequency not defined.
Cardiovascular: Cardiac arrhythmia, cardiac failure
Central nervous system: Coma, confusion, dizziness, drowsiness, dysarthria, headache, hyperreflexia, paresis, paresthesia, psychosis, restlessness, seizure, vertigo
Dermatologic: Skin rash
Endocrine & metabolic: Cyanocobalamin deficiency, folate deficiency
Hepatic: Increased liver enzymes
Hypersensitivity: Hypersensitivity reaction
Neuromuscular & skeletal: Tremor
Concerns related to adverse effects:
• CNS effects: Has been associated with dose-related CNS toxicity, including seizures, psychosis, depression, and confusion; decrease dosage or discontinue use if occurs. Pyridoxine may be coadministered to prevent/treat CNS effects.
• Skin reactions: Allergic dermatitis may occur; reduce dose or discontinue use if allergic dermatitis develops.
• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.
• Alcoholism: Use with caution in patients with a history of chronic alcoholism; increased risk of seizures.
• Mental illness: Use with caution in patients with depression, severe anxiety, and/or psychosis.
• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment may be necessary. Use is contraindicated in severe renal insufficiency.
Concurrent drug therapy issues:
• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.
• Patients with potential for vitamin deficiency: Use with caution in patients with potential vitamin B12 and/or folate deficiency (malnourished, chronic anticonvulsant therapy, or elderly).
Periodic renal, hepatic, hematological tests, and plasma cycloserine concentrations; assess neuropsychiatric status at monthly intervals and more frequently if symptoms occur (ATS 2003).
Pregnancy Risk Factor
Adverse events have not been observed in animal reproduction studies. Cycloserine crosses the placenta and can be detected in the fetal blood and amniotic fluid. The American Thoracic Society recommends use in pregnant women only if there are no alternatives (CDC 2003).
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Have patient report immediately to prescriber signs of depression (suicidal ideation, anxiety, emotional instability, or confusion), behavioral changes, aggressive behavior, fatigue, headache, change in balance, confusion, memory impairment, dizziness, seizures, muscle weakness, shortness of breath, excessive weight gain, swelling of arms or legs, severe loss of strength and energy, change in speech, tremors, or burning or numbness feeling (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer:Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about cycloserine
- Cycloserine Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: streptomyces derivatives
Other brands: Seromycin